Status:
COMPLETED
A Study Comparing Xalacom And Xalatan In Patients With Primary Open Angle Glaucoma (POAG) Or Ocular Hypertension (OH).
Lead Sponsor:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Conditions:
Glaucoma
Ocular Hypertension
Eligibility:
All Genders
20+ years
Phase:
PHASE3
Brief Summary
This study will examine the efficacy and safety of Xalacom comparing with those of Xalatan in Japanese patients with POAG or OH, in order to show superiority of Xalacom over Xalatan in efficacy and si...
Eligibility Criteria
Inclusion
- Intraocular pressure is 18 mmHg or more at baseline after treatment with Xalatan for 4 weeks or more.
Exclusion
- History of no-response to timolol
- History of trabeculectomy
- History of other ocular surgery including ALT, SLT,and trabeculotomy within 6 months
Key Trial Info
Start Date :
November 14 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2007
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT00383019
Start Date
November 14 2006
End Date
October 1 2007
Last Update
September 8 2021
Active Locations (54)
Enter a location and click search to find clinical trials sorted by distance.
1
Nomura Eye Clinic
Ichinomiya, Aichi-ken, Japan, 491-0837
2
Matsusura Eye Clinic
Ichinomiya, Aichi-ken, Japan, 491-0858
3
Yasuma Eye Clinic
Nagoya, Aichi-ken, Japan, 460-0011
4
TANABE Eye Clinic
Nagoya, Aichi-ken, Japan, 466-0054